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Abstract Heart rate is an important contributor in the
pathophysiology of both coronary artery disease (CAD)
and heart failure (HF). Ivabradine is an anti-anginal and
anti-ischaemic agent, which selectively and specifically
inhibits the If current in the sino-atrial node and provides
pure heart rate reduction without altering other cardiac
parameters, including conduction, and without directly
affecting other haemodynamic parameters. It is approved
for the treatment of CAD and HF. This article summa-
rises the pharmacological properties, pharmacokinetics,
clinical efficacy and tolerability of ivabradine in the
treatment of CAD and HF, and presents evidence dem-
onstrating that the pharmacological and clinical properties
and clinical efficacy of ivabradine make it an important
therapeutic choice for patients with stable CAD or HF.
The positive effect of ivabradine on angina pectoris
symptoms and its ability to reduce myocardial ischemia
make it an important agent in the management of patients
with stable CAD or chronic HF. Further studies are
underway to add to the already robust evidence of iva-
bradine for the prevention of cardiovascular events in
patients with CAD but without clinical HF. The SIG-
NIFY (Study assessInG the morbidity–mortality beNefits
of the If inhibitor ivabradine in patients with coronarY
artery disease) trial includes patients with stable CAD
and an LVEF above 40 %, with no clinical sign of HF,
and is investigating the long-term effects (over a period
of 48 months) of ivabradine in a large study population.
So far, this study has included more than 19,000 patients
from 51 countries.
1 Introduction
Although considerable progress has been made in the
management and outcome of patients with cardiovascular
disease, important challenges remain. Coronary artery
disease (CAD) and heart failure (HF) are leading causes of
death and disability despite advances in the prevention and
treatment of these diseases. Cardiovascular disease,
including CAD and HF, represents a huge public health
problem globally. Over the next several decades, the
prevalence of both CAD and HF is expected to increase,
mostly because of an aging population and better survival
after acute coronary events [1].
Heart rate is an important contributor in the patho-
physiology of both CAD and HF and is being increas-
ingly recognised as a modifiable risk factor in patients
with cardiovascular disease [2–5]. There are many
mechanisms through which an elevated heart rate might
directly affect cardiovascular risk, including increased
myocardial oxygen demand, energy depletion, acceler-
ated atherosclerosis, and increased risk of plaque rupture
[6]. This makes reduction of heart rate an important
therapeutic target in patients with CAD and/or HF.
Ivabradine is the first member of a new group of drugs,
the specific heart rate-lowering agents, to be introduced
into clinical use. Ivabradine acts by selectively inhibit-
ing the ionic current If, which modulates pacemaker
activity in the sino-atrial node, providing pure heart rate
reduction [7].
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This article summarises the pharmacological properties,
pharmacokinetics, clinical efficacy and tolerability of iva-
bradine in the treatment of CAD and HF.
2 Mechanism of Action
Heart rate is normally determined by the rate of sponta-
neous diastolic depolarization of myocytes in the sino-
atrial node [8]. The spontaneous slow diastolic depolar-
ization drives membrane potential towards a threshold that
triggers an action potential. The rate of spontaneous dia-
stolic depolarization is significantly influenced by If, a
mixed sodium–potassium current involving ion movement
across so-called f-channels, which are activated by hyper-
polarization, and the opening of which is dependent on the
intracellular availability of cyclic adenosine monophos-
phate [8].
Ivabradine directly and selectively inhibits the If current,
reducing diastolic depolarization rate and heart rate
(Fig. 1) [9–11]. Ivabradine enters and blocks the channel
from the cytoplasmic side of the membrane, preferentially
when the channel is in the open state [10]. As a result of
this use-dependent inhibition, the reduction in the rate of
pacemaker activity induced by ivabradine must be more
important at a higher firing rate, as has already been sug-
gested [10, 12, 13].
The selective binding of ivabradine to If channels makes
it a pure heart-rate–reducing agent. The specificity of iva-
bradine for the If current ensures that ivabradine has no
direct effects on myocardial contractility (or relaxation),
ventricular repolarization or intracardiac conduction [14,
15]. The mode of action of ivabradine allows the drug’s
effect to be enhanced when necessary in clinical practice
without affecting other aspects of cardiac function and with
only a minor risk (1–4 %) of excessive bradycardia. Some,
but not all, computational models show that ivabradine
doses sufficient to cause near-complete If inhibition can
reduce heart rate substantially without abolishing sponta-
neous diastolic depolarization and associated action
potentials [16–18]. In vitro studies have confirmed that full
If block cannot occur in a clinical setting with ivabradine,
because at therapeutic concentrations, If block is less than
50 % [9, 10].
3 Pharmacodynamic Properties
3.1 Effect on Heart Rate
The reduction of heart rate by ivabradine has been char-
acterised in several human studies involving healthy vol-
unteers and patients, and in several pooled analyses of data
from multiple studies [19–21]. These studies have shown
that the heart rate reduction with ivabradine is dependent
on dose and baseline heart rate.
Treatment with ivabradine was associated with a
decrease in 24-h heart rate of 6.3 ± 9.5 beats per minute
(bpm) at last assessment versus no change with placebo
(0.4 ± 7.2 bpm, p \ 0.001) in a 6-month Holter substudy
of the BEAUTIFUL (morBidity-mortality EvAlUaTion of
the If inhibitor ivabradine in patients with coronary disease
and left-ventricULar dysfunction) trial, which examined
the cardiac safety of ivabradine in patients with stable CAD
and left ventricular systolic dysfunction (LVSD) [22]. The
decrease in waking heart rate with ivabradine was greater
than the decrease in heart rate during sleep (6.8 ± 10.4
versus 5.2 ± 8.9 bpm at last visit).
Another recent study in 23 healthy volunteers (aged
19–63 years) evaluated the effect of ivabradine 7.5 mg
twice daily on heart rate over 24 h and demonstrated a
significant reduction in heart rate through 24 h, while
maintaining the circadian heart rate pattern (Clinical data
from IRIS, EudraCT number: 2011-001665-40; data on
file) (Fig. 2). The INITIATIVE (INternatIonal TrIal of the
AnTi-anginal effects of IVabradinE compared to atenolol)
trial, involving 939 patients with stable angina, showed that
ivabradine significantly reduced heart rate after 1 and
4 months of treatment, at rest and at peak exercise [23]. At
rest, heart rate was reduced by 14.3 bpm in the ivabradine
7.5 mg twice daily group compared with 15.6 bpm in the
atenolol 100 mg once daily group.
Heart rate reduction with ivabradine in stable angina
patients was maintained with long-term treatment in a
randomized, double-blind study in 386 patients treated
with ivabradine (either 5 or 7.5 mg twice daily) for 1 year
[24]. Both doses of ivabradine were associated with a
substantial reduction in resting heart rate: 10 bpm with
ivabradine 5 mg twice daily (from 71 to 62 bpm) and
Fig. 1 Mode of action of ivabradine: by inhibiting ion flow though
the f-channel, ivabradine reduces the slow diastolic depolarization
phase of the action potential of sino-atrial node cells, thereby
reducing heart rate. Reproduced with permission from Canet et al.
[11]
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12 bpm with ivabradine 7.5 mg twice daily (from 71 to
59 bpm) [24].
The dependence of If inhibition with ivabradine on
baseline heart rate suggests that heart rate slowing should
be greatest in patients with the highest pre-treatment heart
rate. This was corroborated by data in 2,351 patients, which
showed that the magnitude of heart rate reduction was
directly related to baseline heart rate, for each dose of
ivabradine [16].
3.2 Anti-Ischaemic Effect
By reducing heart rate, ivabradine reduces myocardial
oxygen demand. It also maximizes oxygen supply and
myocardial perfusion by prolonging diastolic time and by
enabling coronary vasodilation during exercise [25, 26]. In
contrast, b-blockers tend to prolong systole because of their
negative effect on myocardial contractility. In conse-
quence, diastole is shorter with b-blockers than with iva-
bradine at rest and during exercise for a similar heart rate
reduction [25, 26].
Adequate relaxation of left ventricular (LV) myocar-
dium after systolic contraction is important in facilitating
diastolic LV filling, particularly during exercise. Though it
caused similar reductions in heart rate at rest and during
exercise to those achieved by atenolol in an animal model,
ivabradine did not alter the relaxation time constant at rest
or during exercise, and gave results similar to the saline
control [27]. Furthermore, despite a similar effect on heart
rate, b-blockade resulted in constriction of large and small
coronary arteries during exercise, while vasodilation was
not affected by ivabradine [28]. Ivabradine also signifi-
cantly reduces cardiac energy consumption and preserves
redox potentials during ischaemia by reducing heart rate
[29].
In a preclinical setting, ivabradine has been shown to
improve regional ischaemia to a greater extent than the
b-blocker propranolol. In an animal model simulating
stable angina pectoris, ivabradine and propranolol (both at
doses producing similar reductions in heart rate) reduced
exercise-associated ST-segment shift in the ischaemic
region by approximately 80 %, but ivabradine preserved
systolic shortening to a significantly greater degree than
propranolol (p \ 0.05) [30].
Ivabradine has been shown to improve myocardial
stunning in dogs [31, 32]. When therapy was administered
before the ischaemic insult, atenolol and ivabradine both
reduced post-ischaemic stunning compared with saline
control, by reducing the degree of exercise-induced
ischaemia [32]. However, when administered soon after the
ischaemic insult with part of the myocardium in the stun-
ned state, ivabradine improved myocardial contractility,
but because of its negative inotropic action, atenolol sig-
nificantly exacerbated contractile dysfunction [32].
The effect of ivabradine in acute myocardial infarction
(MI) has also been explored [33]. Acute MI was modelled
by hypoperfusing the myocardial region supplied by the
left anterior descending coronary artery for 90 min and
then reperfusing for 120 min. Intravenous ivabradine
0.6 mg/kg, administered before the ischemic episode,
reduced the size of the resulting infarct from 35 % of the
area at risk in saline controls to 19 %. Ivabradine also
reduced infarct size when given after the onset of ischemia
or just before reperfusion. When given 15–20 min after the
onset of ischemia, ivabradine also improved regional blood
flow and systolic wall thickening [33].
Fig. 2 Change from baseline in
mean heart rate over 24 h after
treatment with ivabradine
7.5 mg twice daily in
volunteers. bpm beats per
minute. Clinical data from the
IRIS trial. EudraCT record
2011-001665-40 (data on file)
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3.3 Effects on Ventricular Function and Structure
Several studies have investigated the longer-term effects of
ivabradine on myocardial structure and function in models
of HF after induction of experimental MI [34–36]. These
studies have highlighted the potential of ivabradine to
prevent negative cardiac effects following MI. Ivabradine,
given 7 days after MI in a rat model, decreased heart rate
over 90 days without any other haemodynamic effects
[36]. Cardiac output was preserved because of increased
stroke volume. In addition, ivabradine improved cardiac
function by significantly decreasing left ventricular systolic
diameter and increasing fractional shortening [36]. Similar
cardiac benefits were also observed when ivabradine was
given immediately after MI [34] or 2 months after MI [35].
Assessment of the effects of ivabradine on the global
cardiac remodelling process in HF showed that it had
beneficial effects on LV remodelling [37, 38]. Non-clinical
data showed that ivabradine reduced fibrosis in surviving
myocardium, and decreased circulating, as well as local,
renin–angiotensin–aldosterone system (RAAS) stimulation
[34]. In another study in a model of severe HF in rats,
treatment with ivabradine for 3 months improved left
ventricular ejection fraction (LVEF) and end-diastolic
pressure, and reduced interstitial fibrosis in the non-
infarcted LV region [35]. Another study comparing ivabr-
adine and metoprolol for the prevention of experimental
HF in hypertensive mice found that treatment with ivabr-
adine led to a significant improvement in systolic and
diastolic LV function, which was associated with less
cardiac hypertrophy, fibrosis, inflammation and cardiac
apoptosis [39]. Although both drugs reduced heart rate
similarly and only metoprolol reduced systolic blood
pressure, metoprolol did not prevent deterioration in car-
diac function and adverse remodelling, despite a reduction
of the inflammatory stress response [39].
3.4 Vascular Effects
Endothelial dysfunction has been demonstrated in various
cardiovascular diseases, including CAD and congestive
HF. In experimental studies, ivabradine has been shown to
protect endothelial function. Treatment with ivabradine for
3 months prevented deterioration of endothelium-depen-
dent vasodilation in the renal and cerebral arteries in
dyslipidaemic mice [40]. The protective effect seen with
ivabradine was not fully reproduced in mice receiving
metoprolol, despite a similar heart rate reduction. This was
possibly due to inhibition of b-adrenoceptor-mediated
activation of endothelial nitric oxide synthase [40].
Ivabradine also reduced atherosclerotic plaque forma-
tion in transgenic mice models of atherosclerosis. In
transgenic mice with severe hypercholesterolaemia and
atherosclerotic plaques, ivabradine reduced the athero-
sclerotic plaque area in the aortic root (by [40 %) and
ascending aorta (by [70 %) [41].
Aortic compliance was preserved in apolipopro-
tein E-deficient mice treated with ivabradine for 6 weeks
[42]. This improvement could be due to an effect on the
local RAAS system, attenuation of oxidative stress or
modulation of inflammatory cytokine expression [42].
Irregular shear and mechanical stress, which are associated
with elevated heart rate, might damage vascular endothe-
lium, leading to dysfunction and atherogenesis [43].
4 Pharmacokinetic Properties
Ivabradine exhibits linear pharmacokinetics over an oral
dose range of 0.5–24 mg, with rapid absorption after
administration of a single oral dose [44]. In fasting con-
ditions, the time to peak drug concentration is approxi-
mately 1 h, with an absolute bioavailability of the film-
coated tablets of around 40 % following gastrointestinal
and hepatic first-pass metabolism [44]. In fed conditions,
the time to peak plasma drug concentration is prolonged by
approximately 1 h and the plasma concentration of ivabr-
adine is increased by 20–30 %.
Approximately 70 % of ivabradine is plasma protein
bound. At steady state, after multiple doses of 5 mg twice
daily, the maximum plasma concentration of ivabradine is
22 ng/mL and the mean plasma concentration is 10 ng/mL.
Ivabradine has a half-life of 2 h in plasma and an effective
half-life of 11 h. Renal clearance of ivabradine is 70 mL/
min, and the total clearance is 400 mL/min. After oral
administration, approximately 4 % of the ivabradine dose
is excreted unchanged in urine.
Compared with younger individuals, no appreciable
differences in the pharmacokinetic profile of ivabradine
were observed in the elderly (aged C65 years) or very
elderly (C75 years). Renal impairment (creatinine clear-
ance 15–60 mL/min) has a minimal effect on the phar-
macokinetics of both ivabradine and its main metabolite, as
renal clearance accounts for a small part (20 %) of the
elimination of both products.
As regards hepatic impairment and ivabradine, patients
with mild hepatic impairment require no dose adjustment.
Caution is advocated when treating patients with moderate
hepatic impairment, and ivabradine is contraindicated in
patients with severe hepatic insufficiency (as a substantial
increase in systemic exposure is predicted) [44].
Ivabradine is extensively metabolised by the cyto-
chrome P450 (CYP) enzyme CYP3A4. It is a very weak
inhibitor of this enzyme and has no apparent influence on
the metabolism and plasma concentrations of other
CYP3A4 substrates. Conversely, CYP3A4 inhibitors and
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agonists have been shown to affect ivabradine plasma
concentrations, so the concomitant use of strong CYP3A4
inhibitors with ivabradine is contraindicated. Proton pump
inhibitors, sildenafil, 3-hydroxy-3-methyl-glutaryl-CoA
(HMG-CoA) reductase inhibitors, dihydropyridine cal-
cium-channel blockers, digoxin and warfarin have not
demonstrated any clinically significant effect on the phar-
macokinetics and pharmacodynamics of ivabradine in
drug–drug interaction studies [44].
5 Efficacy of Ivabradine in Coronary Artery Disease
5.1 Anti-Anginal and Anti-Ischaemic Efficacy
The anti-anginal and anti-ischemic efficacy of ivabradine
has been confirmed in patients with stable angina in clinical
studies comparing it either with placebo or with standard
anti-anginal agents (Table 1).
5.1.1 Monotherapy
In a placebo-controlled, randomized, dose-ranging study
conducted in 360 patients with stable CAD and chronic
stable angina, Borer et al. [19] showed that ivabradine
produced dose-dependent improvements in exercise toler-
ance parameters. At 2 weeks, ivabradine 5 and 10 mg
twice daily significantly improved the time to 1-mm ST-
segment depression compared with placebo (by 44.1 and
46.2 vs 9.0 s, p = 0.016). This reduction in angina and
ischemia was associated with significant reductions in rate-
pressure product at peak exercise (p = 0.011) and increases
in total work performed in an exercise tolerance test [ETT]
(p = 0.019) among ivabradine-treated patients; both
changes showed significant dose-dependence (p = 0.002
for both) [19]. Furthermore, in the open-label extension
phase (2–3 months) of this study, ivabradine reduced
angina attacks from 4.14 to 0.95 attacks per week
(p \ 0.001) and consumption of short-acting nitrates from
2.28 to 0.50 U per week (p \ 0.001) [19].
Ivabradine was compared directly with the b-blocker
atenolol in INITIATIVE, a randomized, double-blind,
parallel-group trial involving 939 patients [23]. After
16 weeks of treatment, patients receiving ivabradine 7.5 or
10 mg twice daily or atenolol 100 mg/day had similar
increases in total exercise duration at trough (?86.8 and
?91.7 vs 78.8 s, p \ 0.001 for non-inferiority) and the
number of angina attacks per week (-2.2 and -2.3 vs -2.7
attacks per week) [23]. Even though ivabradine was non-
inferior, after 4 months of treatment, all ETT parameters
(time to limiting angina, time to angina onset, and time to
1-mm ST-segment depression) tended to have improved
more with ivabradine than with atenolol, resulting in a
significantly greater increase in exercise capacity per beat
reduction in heart rate with ivabradine than with atenolol.
Heart rate was reduced by 14.3 and 14.3 bpm with ivabr-
adine 7.5 and 10 mg twice daily, versus 15.6 bpm with
atenolol [23].
The anti-anginal and anti-ischemic efficacy of ivabra-
dine (7.5 and 10 mg twice daily) has been compared with
amlodipine 10 mg daily in a large multicentre, interna-
tional, double-blind, randomized, parallel-group trial in
1,195 patients with stable angina [45]. In this study, iva-
bradine was not inferior to amlodipine in improving exer-
cise tolerance as well as increasing time to angina onset,
time to limiting angina and time to 1-mm ST-segment
depression. Similarly, ivabradine was not inferior to
amlodipine in preventing angina attacks and limiting
nitrate use; however, ivabradine produced a greater
reduction of rate-pressure product (a surrogate for myo-
cardial oxygen consumption) than amlodipine.
Skalidis et al. [46] assessed the effect of ivabradine
(5 mg twice daily) on coronary blood flow velocity and
coronary flow reserve (CFR) in patients with stable CAD
(n = 21). Coronary blood flow was assessed invasively
using intracoronary Doppler measurements at baseline and
after 1 week of ivabradine treatment. This study showed
that ivabradine significantly reduced heart rate and
improved hyperaemic and resting coronary flow velocity
and CFR in these patients after 1 week of treatment. These
results suggested that in addition to ivabradine having anti-
ischaemic effects in patients with CAD (as previously
shown), it may also have an impact on ischaemic events, as
CFR predicts adverse cardiovascular long-term outcomes
[47].
5.1.2 Combination Therapy
Ivabradine has been shown to provide additional anti-
ischaemic efficacy in patients who are already receiving
standard therapy with b-blockers [48–50]. The double-
blind, randomized, multicentre, placebo-controlled
ASSOCIATE (evaluation of the Antianginal efficacy and
Safety of the aSsociation Of the If Current Inhibitor ivA-
bradine with a beTa-blockEr) trial was conducted in 889
patients with stable angina already receiving atenolol [48].
All included patients had a positive symptom-limited
exercise test while receiving atenolol 50 mg once daily.
These patients were randomized to receive either ivabra-
dine 5 mg twice daily for 2 months, which was then
increased to 7.5 mg twice daily for an additional 2 months
(449 patients), or placebo (440 patients) and underwent
exercise testing at the trough of drug activity at 2 and
4 months. In the ivabradine group, heart rate decreased by
7 bpm during the first 2 months of treatment with 5 mg
twice daily and by 9 bpm with ivabradine 7.5 mg twice
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Table 1 Summary of the principal results of the main publications of ivabradine in coronary artery disease
Publication Study summary
CAD: monotherapy
Borer et al., 2003 [19]
(n = 360)
Randomised, double-blind, placebo-controlled, multicentre study in patients with stable CAD and
chronic stable angina (n = 360). Duration: 2 weeks double-blind ? 2–3 months open-label. Efficacy:
TST and TLA. At 2 weeks, TST increased by 32.0, 44.1 and 46.2 s with ivabradine 2.5, 5 and
10 mg bid vs 9.0 s with placebo (p = 0.016 for 5 and 10 mg bid dose vs placebo). TLA increased by
22.5, 27.2 and 40.8 s with ivabradine 2.5, 5 and 10 mg bid vs 12.7 s with placebo (p = 0.049 for
10 mg bid dose vs placebo). Resting HR and exercise HR decreased significantly with ivabradine 2.5,
5 and 10 mg bid (all p \ 0.05 vs placebo)
INITIATIVE [23]
(n = 939)
Randomised, double-blind, active-controlled, parallel-group, multicentre study in patients with CAD and
stable angina. Duration: 16 weeks. Efficacy: TED during ETT. Change in TED at trough: ?86.8 and
?91.7 s with ivabradine 7.5 and 10 mg bid vs ?78.8 s with atenolol 50–100 mg/day (mean difference
10.3 and 15.7 s; p \ 0.001 for non-inferiority). Change in the number of angina attacks per week at
16 weeks: -2.2 and -2.3 for ivabradine 7.5 and 10 mg bid vs -2.7 for atenolol. Change in resting
HR: -14.3 and -14.31 bpm for ivabradine 7.5 and 10 mg bid vs -15.6 bpm for atenolol
Ruzyllo et al., 2007 [45]
(n = 1195)
Randomised, double-blind, parallel-group, multicentre study in patients with chronic stable angina.
Duration: 3 months. Efficacy: TED during ETT. Change in TED at trough: ?27.6 and ?21.7 s with
ivabradine 7.5 and 10 mg bid vs ?31.2 s with amlodipine 10 mg od (mean difference 1.8 and 6.6 s;
p \ 0.001 for non-inferiority). Change in the number of angina attacks per week: -3.0 and -3.2 for




Randomised, double-blind, placebo-controlled, multicentre study in patients with chronic stable angina.
Duration: 4 months. Ivabradine 5–7.5 mg bid ? atenolol 50 mg od vs placebo ? atenolol 50 mg od.
Efficacy: TED during ETT. Change in TED at trough: ?24.3 s vs ?7.7 s (p \ 0.001). Change in TLA:
?26.0 s vs ?9.4 s (p \ 0.001). Change in TAO: ?49.1 s vs ?22.7 s (p \ 0.001). Change in TST:
?45.7 s vs ?15.4 s (p \ 0.001)
Amosova et al., 2011 [49]
(n = 29)
Randomised, parallel-group, single-blind study in patients with MI and moderate left ventricular systolic
dysfunction. Duration: 2 months. Ivabradine 5–7.5 mg bid ? bisoprolol 5 mg od versus bisoprolol
5–10 mg od. Change in mean resting HR: from 76.6 to 59.3 bpm (p \ 0.001 vs baseline) vs from 75.9
to 60.5 bpm (p = 0.002 vs baseline). Change in 6-min walking test distance: from 388 to 446 m
(p \ 0.001 vs baseline) vs from 386 to 400 m (p = NS)
ADDITIONS [50]
(n = 2330)
Multicentre, open-label, observational study in patients with stable angina pectoris. Duration: 4 months.
Ivabradine 2.5–7.5 mg bid ? b-blocker. Change in resting HR: from 85.0 to 65.6 bpm (p \ 0.0001 vs
baseline). Change in the number of angina attacks per week: -1.4 (p \ 0.0001 vs baseline). Change in
the consumption of nitrates: -1.9 U (p \ 0.0001 vs baseline)
REDUCTION [58]
(n = 4,954)
Multicentre, open-label, observational study in patients with stable angina pectoris. Duration: 4 months.
Ivabradine 2.5–7.5 mg bid ? b-blocker. Change in resting HR: -12.4 bpm (p \ 0.0001 vs baseline).
Change in the number of angina attacks per week: from 2.8 to 0.5 (p \ 0.0001 vs baseline). Change in
the consumption of nitrates: from 3.7 to 0.7 U (p \ 0.0001 vs baseline)
Lo´pez-Besco´s et al., 2007 [24]
(n = 386)
Randomised, double-blind, parallel-group, multicentre study in patients with chronic stable angina on
concomitant therapy (excluding b-blockers). Duration: 12 months. Ivabradine 5 or 7.5 mg bid. Change
in resting HR: -9.7 and -12.3 bpm. Change in the number of angina attacks per week: -1.9 and
-1.2. Change in the consumption of nitrates: -1.2 and -1.7 U
Skalidis et al., 2011 [46]
(n = 21)
Prospective study in patients with stable CAD. Duration: 1 week. Ivabradine 5 mg bid plus current
medication. HR: from 78 to 65 bpm (p \ 0.01). Hyperaemia CFV: from 53.5 to 57.9 cm/s (p \ 0.01).




Multicentre, open-label, observational study in elderly patients ([80 years old) with stable angina
pectoris. Duration: 4 months. Ivabradine 2.5–7.5 mg bid ? b-blocker. Change in resting HR:
-12.0 bpm (p \ 0.0001 vs baseline). Change in the number of angina attacks per week: from 3.0 to




Pooled analysis of five randomised, double-blind, parallel-group studies in patients with angina pectoris.
Duration: 3–4 months. Ivabradine 5–10 mg bid. Change in resting HR: -14.5 % (11.3 bpm) in all
patients; reduction of 12.4–16.3 % in subpopulations (no difference between groups). Change in the
number of angina attacks per week: -59.4 % in all patients; reduction of 51 % to 70 % in
subpopulations (no difference between groups). Change in the consumption of nitrates: -53.7 % in all
patients; reduction of 0.4 to 3.4 U/week in subpopulations
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daily. Ivabradine significantly increased the total exercise
duration as well as all other exercise test criteria such as
time to limiting angina, time to angina onset and time to
1 mm ST-segment depression (p \ 0.001) compared with
placebo (Fig. 3) [48]. Significant improvements were seen
with ivabradine 5 mg twice daily after 2 months of treat-
ment but were more pronounced after up-titration to
7.5 mg twice daily. The treatment with ivabradine was well
tolerated, and 90 % of patients were up-titrated to 7.5 mg
twice daily after the first 2 months. This study clearly
demonstrated that ivabradine treatment in patients with
stable angina receiving the b-blocker atenolol resulted in a
significant long-term improvement in total exercise dura-
tion in standardized Bruce protocol exercise testing. A
recent analysis of this study extended these findings and
demonstrated that ivabradine treatment resulted in
improvements in all ETT criteria relative to placebo in
patients with stable angina pectoris with resting heart rates
above and below 65 bpm [51].
A pilot study compared the anti-anginal and anti-
ischemic efficacy and tolerability of ivabradine (7.5 mg
twice daily) in combination with the b-blocker bisoprolol
(5 mg once daily) versus bisoprolol 10 mg/day in 29
patients with stable angina [49]. After 2 months of therapy,
the mean resting heart rate decreased similarly in both
groups (from 76.6 to 59.3 bpm [p \ 0.001] vs from 75.9 to
60.5 bpm [p = 0.002]). However, addition of ivabradine
was more efficient for improvement of exercise capacity, as
shown by the results of the 6-min walking test (from 388 to
446 m [p \ 0.001] vs from 386 to 400 m) and an ETT
(workload increased from 5.9 to 7.0 metabolic equivalents
with ivabradine ? bisoprolol, p = 0.004, vs 5.7 to 6.2
metabolic equivalents with bisoprolol alone, p = 0.141).
Because of the small size of the study, its results should be
viewed with caution and as hypothesis generating in nature.
Nevertheless, they do suggest that the combination of
ivabradine and a b-blocker is preferable to treatment with a
b-blocker alone in patients with stable angina [49].
The non-interventional, multicentre, open-label ADDI-
TIONS (prActical Daily efficacy anD safety of procoralan
In combinaTION with beta blockerS) trial followed 2,330
German patients with stable angina pectoris receiving b-
blockers who initiated treatment with ivabradine 5–7.5 mg
twice daily [50]. This study demonstrated that adding
ivabradine to standard therapy with a b-blocker signifi-





Pooled analysis of eight multicentre, randomised, double-blind studies in patients with stable angina.
Duration: 2 weeks to 1 year. Ivabradine 2.5–20 mg bid. Change in resting HR: -11.3 bpm in patients
without diabetes mellitus vs -11.6 bpm in patients with diabetes mellitus. Change in the number of
angina attacks per week: -2.2 in patients without diabetes mellitus vs -2.0 in patients with diabetes
mellitus
CAD: with left ventricular dysfunction (BEAUTIFUL)
Main results [59]
(n = 10,917)
Randomised, double-blind, placebo-controlled, multicentre study in patients with CAD and LVEF of
\40 % also receiving conventional CV therapy. Duration: 19 months (median). Ivabradine
5–7.5 mg bid vs placebo. Efficacy: composite endpoint of CV death, admission to hospital for
acute MI and admission to hospital for new-onset or worsening HF. Primary endpoint: 15.4 % vs
15.3 % of patients (p = 0.94). Pre-specified analysis in patients with heart rate C70 bpm (n = 5,392):
hospitalization for MI, 36 % RRR (p = 0.001); coronary revascularization, 30 % RRR (p = 0.016)
Angina subgroup [61]
(n = 1,507)
Post hoc analysis of the BEAUTIFUL trial in patients with stable angina. Duration: 18 months (median).
Ivabradine 5–7.5 mg bid vs placebo. Efficacy: composite endpoint of CV death, admission to hospital
for acute MI and admission to hospital for new-onset or worsening HF. Primary endpoint: 24 % RRR
(p = 0.05). Hospitalization for MI: 42 % RRR (p = 0.021). In patients with heart rate C70 bpm:
hospitalization for MI, 73 % RRR (p = 0.002); coronary revascularization, 59 % RRR
ECHO substudy [62]
(n = 590)
Echocardiographic substudy of BEAUTIFUL. Duration: 3–12 months. Ivabradine 5–7.5 mg bid vs
placebo. Efficacy: LVEDVI. Change in LVEDVI: -1.48 vs ?1.85 mL/m2 (p = 0.018). Change in
LVEF: 2.00 vs 0.01 % (p = 0.009)
Holter substudy [22]
(n = 840)
Holter substudy of the BEAUTIFUL trial. Duration: 6 months. Ivabradine 5–7.5 mg bid vs placebo.
Efficacy: 24-h HR reduction. HR reduction: 6.3 vs 0.4 bpm (p \ 0.001). In ivabradine group, waking
vs sleeping HR reduction was 6.8 vs 5.2 bpm. Incidence of severe bradycardic episodes (\30 bpm)
during waking or sleep was B1 % in both groups. More ivabradine patients than placebo patients had
HR \40 or \50 bpm, but there was no between-group difference in episode severity
bid twice daily, bpm beats per minute, CAD coronary artery disease, CFV coronary flow velocity, CV cardiovascular, ETT exercise tolerance test, HF heart
failure, HR heart rate, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, MI myocardial infarction, NS not
significant, od once daily, RRR relative risk reduction, TAO time to angina onset, TED total exercise duration, TLA time to limiting angina, TST time to
1-mm ST-segment depression
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4 months), the number of angina attacks per week (from
1.7 attacks to 0.3 attacks per week) and nitrate consump-
tion (from 2.3 to 0.4 U per week) over 4 months of treat-
ment (all p \ 0.0001) [50].
Finally, the results of a long-term trial investigating the
efficacy and tolerability of add-on ivabradine demonstrated
that the initial efficacy observed with ivabradine is main-
tained over a longer period of time (12 months) in patients
with chronic stable angina receiving concomitant therapy
with anti-anginal therapies such as long-acting nitrates,
molsidomine, nicorandil, trimetazidine or dihydropyridine
calcium-channel blockers [24]. In both ivabradine treat-
ment groups, there was a significant reduction in resting
heart rate (from 72.4 to 62.7 bpm and from 71.8 to
59.4 bpm with ivabradine 5 and 7.5 mg twice daily). Fur-
thermore, the mean number of angina attacks per week
decreased significantly by more than 50 % after
12 months’ treatment with ivabradine (p \ 0.001), and
more than 80 % of patients had no attacks or only one
angina attack per week after 12 month of therapy (com-
pared with 58 % of patients at baseline) [24].
Combination therapy is widely used in clinical practice
in order to achieve adequate control of angina, and the
majority of patients receive two or more anti-anginal drugs.
However, clinical trials evaluating combination therapy
have yielded inconsistent results [52–55]. Most studies
have been small, and many have not shown significant
benefits with combinations as opposed to single-drug
therapy. The ASSOCIATE study has demonstrated that
addition of ivabradine to b-blockers provides further clin-
ical benefits, and this might be considered one of the best
evidence-based combination therapies for angina patients.
Furthermore, the ADDITIONS study confirmed that com-
bining ivabradine with b-blocker therapy was efficient and
well tolerated in everyday clinical practice.
The proven anti-anginal and anti-ischemic efficacy of
ivabradine has led to its approval for the treatment of
patients with stable angina pectoris in normal sinus rhythm
with a heart rate[60 bpm who are inadequately controlled
with an optimal dose of b-blocker or who are unable to
tolerate b-blockers, or for whom the use of b-blockers is
contraindicated.
5.1.3 Special Populations
Ivabradine provides anti-anginal efficacy in a wide range of
patients, including elderly patients [56] or those with
concomitant diseases [21] such as diabetes [57]. An ana-
lysis of the REDUCTION (Reduction of ischaemic Events
by reDUCtion of hearT rate In the treatment Of stable
aNgina with ivabradine) study showed that ivabradine was
effective in patients older than 80 years of age [56]. This
open-label, multicentre, non-interventional subanalysis of
382 patients with stable angina pectoris receiving ivabra-
dine showed that ivabradine therapy over 4 months sig-
nificantly reduced angina pectoris episodes (from 3.0 to 0.8
per week), heart rate (from 83.0 to 71.0 bpm) and the
consumption of short-acting nitrates (from 4.2 to 1.2 U per
week) [all p \ 0.0001 vs baseline] [56, 58].
Furthermore, ivabradine is effective in subpopulations
of patients with stable angina pectoris and various con-
comitant diseases [21]. In a pooled analysis of five ran-
domized studies investigating the efficacy of ivabradine in
patients with angina (n = 2,425), the anti-anginal efficacy
of ivabradine was similar across a range of subpopulations
(51–70 % reduction in the frequency of angina attacks in
subpopulations, divided by age, gender, angina severity,
disease characteristics and comorbidities). The efficacy of
ivabradine was maintained in the presence of different
comorbidities: no difference in efficacy was observed in
Fig. 3 Results of the
ASSOCIATE study showing the
effects of ivabradine on exercise
tolerance testing (ETT) after
4 months of treatment in
patients with chronic stable
angina who received the b-
blocker atenolol. Adapted from
Tardif et al. [48]
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patients with asthma or chronic obstructive pulmonary
disease, diabetes mellitus or peripheral vascular disease.
These findings are further supported by an analysis of
the effect of ivabradine in 535 patients with stable angina
and diabetes [57]. The heart rate reduction and anti-
ischaemic and anti-anginal effects seen with ivabradine, as
evaluated by ETTs, were similar in patients with and
without diabetes mellitus [57]. Ivabradine treatment was
not associated with adverse effects on glucose metabolism.
5.2 Prevention of Coronary Events
The BEAUTIFUL study investigated the prognostic effects
of adding ivabradine to standard treatment [59, 60]. This
randomized, double-blind, placebo-controlled study was
conducted in patients with CAD and an LVEF of \40 %
(n = 10,917) randomized to receive ivabradine 5–7.5 mg
twice daily or placebo on top of conventional cardiovas-
cular treatment as recommended by guidelines. In
BEAUTIFUL, the composite primary endpoint of cardio-
vascular death, admission to hospital for acute MI and
admission to hospital for new-onset or worsening HF in the
ivabradine group was similar to that in the placebo group.
In discussing the BEAUTIFUL results, the investigators
underlined that heart rate in the total population was low at
baseline (72 bpm), leading to insufficient heart rate
reduction with ivabradine (5.6 bpm of reduction corrected
for placebo) and therefore limiting the impact of ivabradine
on the primary composite endpoint. However, in a pre-
specified subgroup of patients with an elevated heart rate
(C70 bpm), ivabradine reduced the rate of admission to
hospital for fatal or non-fatal MI by 36 % (hazard ratio
[HR] 0.64, 95 % confidence interval [CI] 0.49–0.84,
p = 0.001; Fig. 4) and coronary revascularization by 30 %
(HR 0.70, 95 % CI 0.52–0.93, p = 0.016) [59].
A post hoc analysis of the trial in patients whose lim-
iting symptom at baseline was angina (n = 1,507) showed
that ivabradine reduced the primary composite endpoint by
24 % (HR 0.76, 95 % CI 0.58–1.00, p = 0.05) and reduced
the rates of hospitalization for MI by 42 % (HR 0.58, 95 %
CI 0.37–0.92, p = 0.021) [61].
The echo cardiographic substudy of the BEAUTIFUL
trial in 590 patients showed that 12 months of therapy with
ivabradine significantly improved LV end-systolic volume
index [LVESVI] (-1.48 vs ?1.85 mL/m2 with placebo,
p = 0.018) and LVEF (?2 % vs no change, p = 0.009).
This reduction in LVESVI was related to the degree of
heart rate reduction with ivabradine [62].
5.3 Effect on Health-Related Quality of Life
The non-interventional, multicentre, open-label ADDI-
TIONS trial also investigated the effects of adding ivabr-
adine to standard therapy with b-blockers on quality of life
[50]. The results of this study highlighted that not only did
the addition of ivabradine have significant anti-anginal and
anti-ischaemic efficacy (as previously discussed) but it was
also associated with an improvement in quality of life, as
assessed using EQ-5D index scores (?0.17, p \ 0.001)
[50]. This improvement in EQ-5D index scores correlated
well with the results of the EQ-5D visual analogue scale
(VAS), for which the general health status throughout the
4 months of treatment improved with ivabradine (VAS
57.4 ± 18.3 points at visit 1, 65.6 ± 16.0 points at visit 2
and 72.7 ± 15.4 at visit 3).
5.4 Efficacy of Ivabradine in Heart Failure
In the first quarter of 2012, ivabradine was approved by the
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Fig. 4 Effect of ivabradine on
risk of hospitalization for
myocardial infarction (MI) in
patients with coronary artery
disease with left ventricular
systolic dysfunction and a heart
rate C70 beats per minute (bpm)
in the BEAUTIFUL trial. HR
hazard ratio. Adapted from Fox
et al. [59]
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HF, on the basis of the results of the Systolic Heart failure
treatment with If inhibitor ivabradine Trial (SHIFT). Fur-
thermore, the updated European Society of Cardiology
(ESC) guidelines for the treatment of chronic HF
recommend ivabradine for patients with sinus rhythm,
LVEF B 35 % and heart rate C70 bpm who remain
symptomatic despite recommended therapy with angio-
tensin-converting enzyme (ACE) inhibitors or angiotensin
Table 2 Summary of the principal results in SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) and its main
publicationsa
Endpoint Ivabradine 5–7.5 mg bid Placebo Hazard ratio p-value
SHIFT main results: Swedberg et al. [65] n = 3,268 n = 3,290
Primary composite endpointb 24 % 29 % 0.82 \0.0001
All-cause hospitalization 38 % 42 % 0.89 0.003
Hospitalization for worsening heart failure 16 % 21 % 0.74 \0.0001
Cardiovascular hospitalization 30 % 34 % 0.85 0.0002
All-cause death 16 % 17 % 0.90 0.092
Cardiovascular death 14 % 15 % 0.91 0.13
Heart failure death 3 % 5 % 0.74 0.014
Analysis in patients with heart rate C75 bpm: Bo¨hm et al. [66] n = 2,052 n = 2,098
Primary composite endpointb 27 % 33 % 0.76 \0.0001
All-cause hospitalization 39 % 44 % 0.82 \0.0001
Hospitalization for worsening heart failure 18 % 24 % 0.70 \0.0001
Cardiovascular hospitalization 31 % 37 % 0.79 \0.0001
All-cause death 17 % 19 % 0.83 0.0109
Cardiovascular death 15 % 17 % 0.83 0.0166
Heart failure death 4 % 6 % 0.61 0.0006
Post hoc analysis of MRA status (n = 6,505): Komajda et al. [68]
Primary composite endpoint in patients with MRA (n = 3,922) 28 % 33 % 0.82(0.78–0.95)f
Hospitalization for worsening heart failure 19 % 23 % 0.77(0.67–0.89)f
Cardiovascular death 16 % 18 % 0.88(0.76–0.94)f
Rehospitalization analysis: Borer et al. [69] n = 3,241 n = 3,264
First hospitalization 16 % 21 % 0.75 \0.001
Second hospitalization 6 % 9 % 0.66 \0.001
Third hospitalization 3 % 4 % 0.71 \0.012
Echocardiographic substudy: Tardif et al. [70]c n = 304 n = 307
LVESV index (mL/m2)d -7.0 -0.9 \0.001
LVESV (mL) -13.0 -1.3 \0.001
LVEDV index (mL/m2) -7.9 -1.8 0.002
LVEDV (mL) -14.7 -2.9 0.001
LVEF (%) 2.4 % -0.1 % \0.001
Health-related quality-of-life analysis: Ekman et al. [73]e n = 968 n = 976
Heart rate (bpm) -14.8 -4.9 \0.0001
KCCQ
Overall summary score 6.7 4.3 \0.001
Clinical summary score 5.0 3.3 0.018
bid twice daily, bpm beats per minute, KCCQ Kansas City Cardiomyopathy Questionnaire, LVEDV left ventricular end-diastolic volume, LVEF
left ventricular ejection fraction, LVESV left ventricular end-systolic volume, MRA mineralocorticoid receptor antagonist
a Values are expressed as percentages or means
b Cardiovascular death or hospitalization for worsening heart failure
c Change from baseline to 8 months
d Primary endpoint of substudy
e Change from baseline to 12 months
f 95 % confidence intervals are shown in brackets
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Fig. 5 Results of the SHIFT
study in patients with chronic
heart failure (HF), showing the
effects of ivabradine on the
cumulative event curves for
(a) the primary composite
endpoint of cardiovascular (CV)
death or hospital admission for
worsening HF, (b) hospital
admission for worsening HF,
and (c) death from HF. HR
hazard ratio. Adapted from
Swedberg et al. [65]
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receptor blockers, b-blockers, or mineralocorticoid recep-
tor antagonists [63]. The key results of the SHIFT trial are
summarised in Table 2.
5.5 Improvement of Clinical Outcomes
SHIFT was a randomized, double-blind, parallel-group,
multicentre, placebo-controlled study, which investigated
the effects of ivabradine (initiated at 5 mg twice daily and
titrated to a maximum of 7.5 mg twice daily) when added
to current guideline-based therapy in 6,558 patients with
symptomatic chronic HF, LV systolic dysfunction
(LVEF B 35 %) and heart rate of 70 bpm or higher [64].
The primary endpoint of SHIFT was a composite of car-
diovascular mortality or hospitalization for worsening HF,
and the median follow-up was 22.9 months.
SHIFT showed that ivabradine significantly reduced the
risk of cardiovascular death and hospitalization due to
worsening HF, compared with placebo, by 18 % (937
[29 %] vs 793 [24 %], HR 0.82, 95 % CI 0.75–0.90,
p \ 0.0001; Fig. 5) [65]. The number needed to treat for
1 year to prevent one primary endpoint was 26. Further-
more, ivabradine reduced the risk of hospitalization for
worsening HF, compared with placebo, by 26 % (672
[21 %] vs 514 [16 %], HR 0.74, 95 % CI 0.66–0.83,
p \ 0.001) and the risk of death related to HF by 26 %
(151 [5 %] vs 113 [3 %], HR 0.74, 95 % 0.58–0.94,
p = 0.014) [65]. Importantly, the favourable effect of
ivabradine on HF events became apparent within 3 months
of initiation of treatment, and the benefits were maintained
through the course of the trial. The effect was consistent
across all pre-specified subgroups (elderly, b-blocker
intake, cause of HF, diabetes mellitus and hypertension
status, and baseline heart rate) [65].
An increase in heart rate is associated with a high risk of
cardiovascular events, and so patients with higher heart rate
are expected to benefit the most from preventive therapy.
This was shown in an analysis of patients enrolled in
SHIFT whose heart rate was C75 bpm [66]. In these
patients, ivabradine significantly reduced the primary
composite endpoint, all-cause mortality, cardiovascular
mortality, HF death and HF hospitalization (Fig. 6). Risk
reduction depended on heart rate after 28 days, with the
best protection for heart rates \60 bpm or reductions
[10 bpm.
Another post-hoc analysis of SHIFT assessed the impact
of background b-blockers on the response to ivabradine
[67]. This analysis demonstrated that there was no evidence
of an influence of b-blocker dose on the placebo-corrected
change of heart rate with ivabradine. However, there was
evidence of a clear effect of baseline heart rate on heart rate
reduction (p \ 0.0001), with the greatest changes in heart
rate being observed in patients with the highest baseline
heart rates [67]. After adjustment for the previously iden-
tified interaction between baseline heart rate and the effect
of treatment with ivabradine, there was no evidence of a
trend across the four dose categories, even in the analysis
adjusting only for baseline heart rate (p = 0.135 for the
primary endpoint, p = 0.19 for hospital admission for
worsening heart failure and p = 0.30 for cardiovascular
death). This analysis indicated that the magnitude of heart
rate reduction by ivabradine beyond what is achieved by a
b-blocker, rather than the background b-blocker therapy
itself, primarily determines subsequent outcome. The
additional heart rate reduction achieved by adding ivabra-
dine to the treatment regimen of patients whose heart rate
was C70 bpm despite b-blockade (as well as those who
could not tolerate b-blockers) was shown to be beneficial
[67].
Another post-hoc analysis of SHIFT assessed the impact
of background mineralocorticoid receptor antagonists
(MRAs) on the response to ivabradine. This analysis
Fig. 6 Effects of ivabradine on
cardiovascular outcomes in
patients with chronic heart
failure (HF) and a baseline heart
rate C75 beats per minute:
subanalysis of the SHIFT study.
The primary composite
endpoint of this study was
cardiovascular death or hospital
admission for worsening HF. CI
confidence interval, HR hazard
ratio. Adapted from Bo¨hm et al.
[66]
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showed that the beneficial effect of ivabradine observed in
the patients with chronic HF enrolled in the SHIFT study
was similar in patients who were receiving MRAs at
baseline and those who were not. This shows that ivabra-
dine improves outcomes in patients receiving multiple
neurohormonal modulation treatments (ACE inhibitor or
angiotensin receptor blocker, b-blocker and/or MRA) and
should be considered in patients receiving these treatments
whose heart rate is C70 bpm [68].
Finally, an analysis of the SHIFT trial investigated the
effect of ivabradine on recurrent hospitalizations for
worsening HF in patients with chronic systolic HF
receiving guideline-based background therapy [69]. This
analysis showed that ivabradine significantly reduced the
likelihood of recurrent hospitalizations for worsening HF.
During the study (median follow-up 22.9 months), ivabr-
adine was associated with a 25 % reduction of the total
number of hospitalizations for worsening of HF (902 vs
1,211 events with placebo, p = 0.0002; Fig. 7). Ivabradine-
treated patients also had a lower risk of a second or third
HF hospitalization (HR 0.66, 95 % CI 0.55–0.79,
p \ 0.001; and HR 0.71, 95 % CI 0.54–0.93, p = 0.012,
respectively). Reduction of recurrent hospitalization for
worsening HF is extremely important, as HF admissions
are not only distressing for patients and their families, but
also significantly affect patients’ quality of life and are the
major driver of the economic burden of heart failure. In
addition, hospitalization itself may not only be the conse-
quence of worse prognosis but may contribute to worse
outcome. Consequently, it is important to quantify the
influence of treatment on these recurrent, non-fatal events
because the true benefit of treatment should be determined
by its effect on all events (including repeat events) and not
just first events.
5.6 Effect on Left Ventricular Remodelling
The echocardiography substudy of the SHIFT trial showed
that ivabradine has a beneficial effect on LV remodelling
and function in patients with chronic HF [70]. This pre-
planned substudy investigated the effects of ivabradine on
the LVESVI and cardiac dimensions in 411 patients who
underwent echocardiography at baseline and after
8 months of treatment. At 8 months, ivabradine treatment
had significantly improved the LVESVI compared with
placebo (-7.0 vs -0.9 mL/m2, difference -5.8, 95 % CI
-8.8 to -2.7, p \ 0.001). Compared with placebo, ivabr-
adine also significantly reduced LV end-systolic volume
(p \ 0.001), LV end-diastolic volume index (p = 0.002)
and LV end-diastolic volume (p = 0.001) and increased
LVEF (p \ 0.001) after 8 months. These results indicate a
reversal of cardiac remodelling with ivabradine. All
changes in LV volumes and LVEF were consistent in all
pre-specified subgroups regardless of the disease aetiology,
baseline LVEF or b-blocker use. The beneficial effect of
ivabradine was observed despite the fact that more than
90 % of the patients were receiving treatment with b-
blockers and RAAS antagonists. As cardiac remodelling is
a central feature of the progression of HF, these results
have important clinical implications.
5.7 Effect on Exercise Capacity and Clinical
Symptoms
Ivabradine improves exercise capacity in patients with HF.
The CARVIVA HF (effect of CARVedilol, IVAbradine or
their combination on exercise capacity in patients with
Heart Failure) study investigated the effects of ivabradine
(up to 7.5 mg twice daily) and the b-blocker carvedilol (up


















































Fig. 7 Cumulative incidence of
hospitalization for worsening
heart failure (mean number of
events per patient) in the SHIFT
study. CI confidence interval,
IRR incidence rate ratio.
*Estimate of rate of
hospitalization over time
(corrected for the competing
risk of death). Adapted from
Borer et al. [69]
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to 25 mg twice daily) or their combination (5/12.5 mg
twice daily) on exercise capacity in 121 patients with HF
receiving a maximal dose of an angiotensin-converting
enzyme (ACE) inhibitor [71]. This prospective, random-
ized, open, blinded endpoint study showed that compared
with carvedilol, ivabradine alone and in combination over
12 weeks improved 6-min walk distance (from 346.7 to
474.8 m and from 358.2 to 453.1 m with ivabradine alone
or in combination with carvedilol, respectively, vs from
379.0 to 435.7 m with carvedilol alone, p \ 0.01 and
p \ 0.02) and exercise capacity, as assessed with a mixed
venous oxygen saturation (MVO2) test. Significant
improvements in peak maximal oxygen consumption (VO2)
and the ventilatory anaerobic threshold (VAT) were also
observed with ivabradine alone and in combination with
carvedilol when compared with carvedilol alone (p \ 0.01
and p \ 0.03, respectively). The New York Heart Associ-
ation (NYHA) functional class improved significantly more
in patients receiving ivabradine alone or in combination
than in those allocated to carvedilol alone.
The effects of ivabradine on exercise capacity, gas
exchange, functional class, quality of life, and neurohor-
monal modulation in patients with ischaemic congestive
HF were demonstrated in a study by Sarullo et al. [72].
This randomized, placebo-controlled study showed that i-
vabradine had a positive effect on exercise capacity and
clinical symptoms in the 60 patients who were enrolled.
The exercise capacity increased from 14.8 to 28.2 min
(p \ 0.0001), and the peak oxygen consumption improved
from 13.5 to 17.9 mL/kg per minute (p \ 0.0001) in the
ivabradine group. NTproBNP levels decreased from 2,356
to 1,434 pg/mL (p = 0.045).
5.8 Effect on Health-Related Quality of Life
Ivabradine has also been shown to improve quality of life
in patients with chronic HF [71–73]. Firstly, patient-
reported global assessment in patients in the SHIFT trial
showed significant improvement in 2,118 patients (72 %)
in the ivabradine group compared with 2,017 (68 %) in the
placebo group (p = 0.0005). There was also significant
improvement in NYHA class at the last recorded value in
887 patients (28 %) on ivabradine versus 776 patients
(24 %) on placebo (p = 0.001) [65]. The Patient-Reported
Outcomes substudy of the SHIFT trial showed that a
reduction in heart rate with ivabradine improved health-
related quality-of-life parameters, as assessed by the dis-
ease-specific Kansas City Cardiomyopathy Questionnaire
(KCCQ) [73]. After 12 months of ivabradine therapy,
significant improvements in health-related quality of life
were shown across all eight dimensions of the KCCQ,
compared with placebo, in patients with chronic HF
(n = 1,944). These changes were observed after 4 months
of treatment and were maintained until the last post-base-
line visit (24 months). Moreover, the improvement in
KCCQ scores seen at 12 months was associated with the
magnitude of the observed heart rate reduction seen with
ivabradine, and this benefit was maintained at 24 months.
An improvement of 5 or more points on the KCCQ is
considered to be clinically meaningful, so this analysis
shows that ivabradine is associated with clinically mean-
ingful improvements in health-related quality of life [73].
The CARVIVA HF study showed that patients receiving
ivabradine alone or in combination with carvedilol had a
better quality of life than those receiving carvedilol alone
[71]. Quality of life was assessed in this study using both a
VAS and the MacNew Quality of Life after Myocardial
Infarction (QLMI) questionnaire. Ivabradine and combi-
nation therapy significantly improved the overall assess-
ment of quality of life from baseline (from 4.3 to 6.7
[p \ 0.01] and from 4.7 to 6.1 [p \ 0.02], respectively). In
contrast, quality-of-life scores did not improve with car-
vedilol (from 4.6 to 4.1) [71]. These findings are further
supported by another study by Sarullo et al. [72], which
also demonstrated that ivabradine improved quality of life.
Compared with placebo, ivabradine significantly improved
Minnesota Living with Heart Failure Questionnaire scores
after 3 months of treatment.
5.9 Effect on Cardiovascular Events in a Pooled
Analysis
Individual trial data from SHIFT and BEAUTIFUL were
pooled to determine the effect of ivabradine on outcomes in
a wide range of patients with LVSD, heart rate C70 bpm,
and CAD and/or HF [74]. The pooled population
(n = 11,897, baseline age 62.3 ± 10.4 years, heart rate
79.6 ± 9.2 bpm, and LVEF 30.3 ± 5.6 %) was well trea-
ted according to current recommendations (87 % received
b-blockers, 90 % received RAAS inhibitors). Median fol-
low-up was 21 months. Treatment with ivabradine led to a
significant 13 % reduction in the relative risk of the SHIFT
primary composite endpoint [cardiovascular mortality or
hospitalization for worsening heart failure] versus placebo
(p \ 0.001), and a 15 % reduction in the relative risk of the
BEAUTIFUL primary composite endpoint [cardiovascular
death, admission to hospital for acute MI, or admission to
hospital for new-onset or worsening heart failure]
(p \ 0.001). The relative risk reduction of the SHIFT
composite endpoint was driven by a 13 % relative risk
reduction in hospitalization for worsening heart failure,
while that of the BEAUTIFUL composite endpoint was
driven by 10 % relative risk reductions in cardiovascular
death and hospital admission for MI. Treatment with iva-
bradine also led to significant reductions in a range of heart
failure outcomes in patients with heart rate C75 bpm
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(n = 7,632 [64 %]) compared with placebo. Cardiovascu-
lar mortality or hospitalization for worsening heart failure
(p \ 0.0001), cardiovascular mortality (p = 0.049), hos-
pitalization for worsening heart failure (p \ 0.0001) and
all-cause mortality (p = 0.048) were all reduced with iva-
bradine in these patients. This analysis also confirmed the
safety of ivabradine in a large population with LVSD,
particularly with regard to bradycardia. It also showed that
regardless of clinical presentation or profile, ivabradine has
an important role in the treatment of patients with LVSD
and elevated heart rate C70 bpm.
6 Safety and Tolerability
Ivabradine has a favourable tolerability profile, as observed
during its clinical development [44, 75]. It is safe and well
tolerated when administered as a monotherapy [19, 23, 45]
or when administered in combination with atenolol [48],
bisoprolol [49], other b-blockers [50, 58] or other cardio-
vascular therapies [24]. Ivabradine was well tolerated in a
range of patient populations, including those with stable
angina, CAD or HF [22, 65].
Ivabradine is also well tolerated in patients with co-
morbidities including asthma and chronic obstructive
pulmonary disease [21, 57] or in patients with diabetes
mellitus, without any particular safety concerns or
adverse effects on glucose metabolism [57]. Another
important advantage of ivabradine is that it can be safely
used in the presence of low blood pressure because it
has no effect on blood pressure or other haemodynamic
parameters.
The two most common adverse events associated with
the recommended doses of ivabradine are bradycardia and
visual symptoms [75]. Bradycardia is an expected adverse
event of any heart rate-reducing treatment. However, in
the clinical programme of ivabradine, only 3–4 % of
patients receiving therapeutic doses of ivabradine (5 or
7.5 mg twice daily) experienced symptomatic bradycar-
dia. Furthermore, there were very low rates of discontin-
uation in these studies due to this adverse event [23, 59,
65]. For example in the SHIFT trial, bradycardia led to
permanent withdrawal from the study of 48 patients (1 %)
on ivabradine versus 10 (\1 %) of those in the placebo
group [59]. A Holter substudy of the BEAUTIFUL trial
investigated the cardiac safety of ivabradine in patients
with stable CAD and LV systolic dysfunction also
receiving b-blockers [22]. In this study, 840 patients who
were enrolled in the BEAUTIFUL trial also underwent
24-h digital ambulatory ECG recording at baseline and
after 1 and 6 months of treatment. There was no increase
in the incidence of conduction and rhythm disturbances
with ivabradine compared with placebo [22]. This study
showed that ivabradine significantly lowers heart rate
without affecting cardiac safety.
The visual symptoms associated with ivabradine are due
to the action of ivabradine on retinal ion channels (Ih
current), which belong to the same family as those
responsible for the If current in the sino-atrial node. In the
clinical trials of ivabradine, visual symptoms (mainly
phosphenes) were reported in a small proportion of
patients. These symptoms were generally mild and
resolved spontaneously during or after treatment. Fewer
than 1 % of patients receiving ivabradine in clinical trials
discontinued treatment because of visual symptoms [19,
23, 24, 45, 48–50, 58, 65].
7 Dosage and Administration
Ivabradine is available in 5 mg and 7.5 mg film-coated
tablets. For the treatment of CAD, the recommended
starting dose of ivabradine is 5 mg twice daily, which can
be up-titrated to 7.5 mg twice daily after 3 or 4 weeks if
the resting heart rate is still above 60 bpm. The dose of
ivabradine can be reduced to 2.5 mg twice daily if the
resting heart rate goes below 50 bpm or if the patient
experiences symptoms related to bradycardia, such as
dizziness, fatigue or hypotension, during treatment with the
recommended daily dose of ivabradine.
For the treatment of chronic HF, the recommended
starting dose of ivabradine is 5 mg twice daily, which can
be titrated up to 7.5 mg twice daily after 2 weeks if the
resting heart rate is still above 60 bpm [44]. If the resting
heart rate is below 50 bpm or if the patient experiences
symptoms related to bradycardia, ivabradine can be
reduced to 2.5 mg twice daily.
A lower starting dose (2.5 mg twice daily) is recom-
mended in patients aged 75 years or older. No dose
adjustment is required in patients with renal insufficiency
and creatinine clearance above 15 mL/min, or in patients
with mild hepatic impairment.
8 Conclusions and Future Perspectives
The pharmacologic properties and clinical efficacy of i-
vabradine make it an important therapeutic choice for
patients with stable CAD or HF. The positive effect of
ivabradine on angina pectoris symptoms and myocardial
ischaemia, and its ability to reduce myocardial ischemia,
make it an important agent in the management of patients
with stable CAD.
Following the results of SHIFT, ivabradine has also
been approved for the treatment of patients with chronic
HF and LVSD who remain symptomatic and therefore are
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still at risk of high mortality despite therapy with con-
ventional agents such as RAAS blockers or b-blockers. The
use of ivabradine improves prognosis, reduces recurrent
hospitalizations and improves quality of life in patients
with chronic heart failure with LVSD.
Further studies are evaluating the efficacy of ivabradine
for prevention of cardiovascular events in patients with
CAD but without clinical HF. The SIGNIFY (Study
assessInG the morbidity–mortality beNefits of the If inhib-
itor ivabradine in patients with coronarY artery disease)
trial includes patients with stable CAD and an LVEF above
40 %, with no clinical sign of HF, and is investigating the
long-term effects (over a period of 48 months) of ivabra-
dine in a large study population [76]. So far, this study has
included more than 19,000 patients from 51 countries. The
results of SIGNIFY will undoubtedly provide further
insights into the role of ivabradine in CAD patients.
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